Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00234273
Other study ID # DCIC 03 09
Secondary ID
Status Terminated
Phase Phase 2
First received October 5, 2005
Last updated June 18, 2013
Start date November 2004
Est. completion date June 2008

Study information

Verified date June 2013
Source University Hospital, Grenoble
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The principal objective is to assess and analyze the effects of a six month programme in Adapted Physical Activity (APA) on physical activity, compliance, and insulin resistance among type 2 diabetics.


Description:

Clinical trial with direct individual profit. Study phase 2. Study center: University Hospital Grenoble Principal investigator: Pr. Serge HALIMI Sponsor: University Hospital Grenoble

The principal objective is to assess and analyze the effects of a six month programme in Adapted Physical Activity (APA) on physical activity, compliance, and insulin resistance among type 2 diabetics.

Secondary objectives are to assess and analyze the effects of a six month programme in APA of:

- arterial tension

- weight, body composition and abdominal perimeter

- quality of life

- treatment dosage

- number of hospitalisation thick a diabetes complication acute for one year and for each patient Compare two exercise's intensity: first lactate threshold (SL1) and crossover (PCGL).

Inclusion criteria:

- type 2 diabetics

- age > 40 years

- first education in Education Diabetics Department of University Hospital Grenoble

- sedentary patients

- HbA1c > 7%-

- BMI > 25

- to be affiliate disease assurance

- to give consent written and inform

Judgment criteria for physical activity compliance:

- leisure time physical activity: Modifiable Activity Questionnaire

- training note-book

Judgment criteria for resistance insulin:

- Crossover (PCGL)

- HOMA and FIRI index

- HbA1c

Programme test: Rehabilitation programme in Adapted Physical Activity (APA)

Programme test period: 6 months

Study total period: 28 months

Study period for each patient: 18 months

Safety criteria: clinical compendium undesirable events


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date June 2008
Est. primary completion date June 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetics

- Age > 40

- First education in the Education Diabetics Department of the University Hospital Grenoble

- Sedentary patients

- Hemoglobin A1c (HbA1c) > 7%

- Body mass index (BMI) > 25

- To be affiliated with disease assurance

- To give written and informed consent

Exclusion Criteria:

- Foot sore < six months

- Renal disease - proteinuria stage

- Contraindication for exercise

- VO2 max > 120% Wassermann standard

- Coronary pathology non-stabilization

- Arteriopathy stage 2 non-compensation

- Osteo-articular crippling problem

- Geographically distant

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Procedure:
Rehabilitation programme in Adapted Physical Activity (APA)

Behavioral:
Therapeutic education primarily focused on dietary


Locations

Country Name City State
France Department of Endocrinology, Diabetology and Nutrition Grenoble Rhône-Alpes
France Endocrinology, Diabetology and Nutrition - University Hospital of Grenoble Grenoble Rhone-alpes
France Endocrinology, Diabetology and Nutrition Department - University Hospital of Grenoble Grenoble
France HALIMI Serge Grenoble

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

References & Publications (5)

Bouvard S, Faure P, Roucard C, Favier A, Halimi S. Characterization of free radical defense system in high glucose cultured HeLa-tat cells: consequences for glucose-induced cytotoxicity. Free Radic Res. 2002 Sep;36(9):1017-22. — View Citation

Halimi S, Charpentier G, Grimaldi A, Grenier JL, Baut F, Germain B, Magnette J. Effect on compliance, acceptability of blood glucose self-monitoring and HbA(1c) of a self-monitoring system developed according to patient's wishes. The ACCORD study. Diabete — View Citation

Halimi S, Wion-Barbot N, Lambert S, Benhamou P. [Self-monitoring of blood glucose in type 2 diabetic patients. What could we propose according to their treatment?]. Diabetes Metab. 2003 Apr;29(2 Pt 2):S26-30. Review. French. — View Citation

Halimi S. [Is a new therapeutic class justified in the treatment of type 2 diabetes?]. Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 2):1S7-11. Review. French. — View Citation

Halimi S. [Therapeutic strategies for type 2 diabetes]. Rev Prat. 2003 May 15;53(10):1079-85. Review. French. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Increase physical activity compliance long-term Modifiable Activity Questionnaire (MAQ 6 months after the beginning of the program No
Primary Lessen insulin resistance HOMA (Homeo-stasis model assessment), HbA1c, PCGL 6 months after the beginning of the program No
Secondary Improve the quality of life Short Form-36 Health Survey Questionnary (SF-36) 6 months after the beginning of the program No
Secondary Improve the arterial tension arterial tension 6 months after the beginning of the program No
Secondary Lessen the weight weight 6 months after the beginning of the program No
See also
  Status Clinical Trial Phase
Completed NCT02158741 - Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes N/A
Recruiting NCT05949008 - Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo Phase 4
Completed NCT01056367 - Resistant Hypertension in Patients With Type-II-Diabetes Mellitus N/A
Completed NCT01027052 - Spices Inhibit the Formation and Absorption of Malondialdehyde From Hamburger Meat N/A
Completed NCT01272804 - Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes Phase 1
Completed NCT00410800 - Insulin Secretory Defects in Pima Indians at High Risk for NIDDM N/A
Not yet recruiting NCT00192803 - Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs Phase 4

External Links